- ANGLE Plc (AGL)[AGL], a specialist medtech company listed on the London Stock Exchange AIM market is to present its performance in the past year as well as its plans for growth and development at the free-to-attend Shares investor evening in London on 15th December 2015.

About ANGLE Plc (AGL) ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. ANGLE secured CE Mark regulatory authorisation for the clinical market in December 2013 and FDA authorisation work is in progress.

The primary application is the capture of circulating tumour cells (CTCs) in patient blood for early detection of cancer, personalised cancer treatment, monitoring of cancer patients during treatment and post-treatment monitoring of cancer patients in remission.

For more information, visit

At 1:03pm: [LON:AGL] Angle PLC share price was 0p at 75.5p

Story provided by